Trump to impose 100% tariff on China starting November 1
SOLANA BEACH, California - ClearPoint Neuro, Inc. (NASDAQ:CLPT), a medical device company with a market capitalization of approximately $597 million and impressive year-to-date returns of 42%, announced Wednesday the development of a proprietary Robotic Neuro-Navigation System designed to support minimally invasive cranial surgical procedures, including cell and gene therapy infusions. According to InvestingPro data, the company has demonstrated strong momentum, with the stock trading near its 52-week high.
The system will enable ClearPoint’s navigation software to operate the KUKA LBR Med Robotic Arm for various neurosurgical applications. The company plans to demonstrate a prototype at the 75th Annual Congress of Neurological Surgeons in Los Angeles from October 13-15. With revenue growth of nearly 20% in the last twelve months and a healthy current ratio of 7.3, InvestingPro analysis suggests the company maintains a strong financial position to support this development. Discover 12 more exclusive InvestingPro Tips for CLPT and access comprehensive analysis in the Pro Research Report.
According to Jeremy Stigall, CBO and GM of the Biologics and Drug Delivery Business at ClearPoint, the new robotic system aims to provide both consistency and flexibility for commercial launches of cell and gene therapies.
The platform will offer three different hardware options for executing surgical plans: traditional MRI-guided technique, the new ClearPoint 3.0 iCT guided technique, and the future robotic-assisted technique using iCT. All options will utilize the same ClearPoint software workflow.
Joe Burnett, President and CEO of ClearPoint Neuro, stated that the company’s approach leverages KUKA’s FDA-cleared and CE-marked robotic arm technology rather than developing a system from scratch, which he said "dramatically decreases the development cost and accelerates our speed to market."
The system has not yet been submitted to any regulatory body. ClearPoint aims to commercialize the technology in coordination with the approval of multiple neuro cell and gene therapies currently under FDA expedited review.
Based on a press release statement, the company positions this development as part of its strategy to support biopharmaceutical partners preparing for commercial launches of new cell and gene therapies. While operating with moderate debt levels and maintaining strong liquidity, investors should note that analysts currently don’t expect profitability this year, according to InvestingPro data.
In other recent news, ClearPoint Neuro reported its Q2 2025 earnings, which fell short of forecasts. The company posted an earnings per share of -0.21 USD, slightly missing the forecast of -0.2 USD, and reported revenue of 9.2 million USD, just below the expected 9.23 million USD. Despite these misses, the company demonstrated resilience in aftermarket trading. In another development, ClearPoint Neuro received FDA 510(k) clearance for its Prism Neuro Laser Therapy System to include 1.5T MRI guidance, expanding from the previously cleared 3T MRI guidance. This expanded labeling could significantly increase the system’s market opportunity in the United States, where 1.5T MRI systems account for a large portion of clinical use. Additionally, ClearPoint Neuro announced the appointment of Dr. Paul Larson as Chief Medical Officer, effective January 2026. Dr. Larson will continue his work at the University of California San Francisco and Banner Hospital, University of Arizona, while maintaining his advisory role with the company. These developments reflect ClearPoint Neuro’s ongoing efforts to expand its market reach and strengthen its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.